

Application No.: 10/001,469

Docket No.: 511582002420

**REMARKS**

The claims have been amended in conformance with the agreement reached with Examiner Davis.

In a previous telephone conversation between Examiner Davis and the undersigned concerning possible amendments to the claims, Dr. Davis kindly indicated that the claims would be allowable if the limitation of claim 55 were included in claim 48. Applicants greatly appreciate the agreement by Dr. Davis that the activity might include either the already mentioned cAMP accumulation from claim 48 or, in the alternative, 101P3A11-mediated ERK phosphorylation of claim 55.

Applicants understand the reluctance of the Office to issue the open language "downstream signaling effects thereof" without further qualification. However, there are additional identified downstream signaling effects disclosed in the specification besides 101P3A11-mediated ERK phosphorylation. These have now been agreed to be listed in claim 48 as alternatives to ERK phosphorylation.

Support for the involvement of p38 phosphorylation in the downstream signaling pathway is found on pages 105-106, bridging paragraph. Support for 101P3A11-mediated cell growth is found on page 107, line 20. Support for 101P3A11-mediated G-alpha subunit activation is found on page 107, line 17. Support for 101P3A11-mediated cell adhesion is found in Example 45.

Thus, claim 48 has been provided specific downstream signal activation effects which can be measured and which have been identified in the specification.

Applicants are gratified these modified claims address the concerns of the Office and that proposed claims 48, 50 and 54 are allowable.

Also discussed were problems with the substitute specification, which are now being addressed.

Should there be additional problems noted by the Office, and telephone call to the undersigned would be greatly appreciated.

sd-306092

4

Application No.: 10/001,469

Docket No.: 511582002420

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket No. 511582002420.

Respectfully submitted,

Dated: March 15, 2006

By: Kate H. Murashige  
Kate H. Murashige  
Registration No. 29,959

Morrison & Foerster LLP  
12531 High Bluff Drive  
Suite 100  
San Diego, California 92130-2040  
Telephone: (858) 720-5112  
Facsimile: (858) 720-5125

sd-306092

5